全文获取类型
收费全文 | 72028篇 |
免费 | 7747篇 |
国内免费 | 2705篇 |
专业分类
耳鼻咽喉 | 182篇 |
儿科学 | 620篇 |
妇产科学 | 274篇 |
基础医学 | 3185篇 |
口腔科学 | 1320篇 |
临床医学 | 6186篇 |
内科学 | 7329篇 |
皮肤病学 | 1081篇 |
神经病学 | 2395篇 |
特种医学 | 1038篇 |
外国民族医学 | 7篇 |
外科学 | 2492篇 |
综合类 | 9774篇 |
现状与发展 | 5篇 |
一般理论 | 6篇 |
预防医学 | 5551篇 |
眼科学 | 718篇 |
药学 | 31858篇 |
45篇 | |
中国医学 | 4666篇 |
肿瘤学 | 3748篇 |
出版年
2024年 | 69篇 |
2023年 | 1178篇 |
2022年 | 1434篇 |
2021年 | 2473篇 |
2020年 | 2681篇 |
2019年 | 2674篇 |
2018年 | 2719篇 |
2017年 | 2994篇 |
2016年 | 2838篇 |
2015年 | 2862篇 |
2014年 | 4858篇 |
2013年 | 7993篇 |
2012年 | 4982篇 |
2011年 | 5122篇 |
2010年 | 4027篇 |
2009年 | 3646篇 |
2008年 | 3521篇 |
2007年 | 3506篇 |
2006年 | 3126篇 |
2005年 | 2801篇 |
2004年 | 2298篇 |
2003年 | 2070篇 |
2002年 | 1626篇 |
2001年 | 1549篇 |
2000年 | 1179篇 |
1999年 | 981篇 |
1998年 | 816篇 |
1997年 | 773篇 |
1996年 | 640篇 |
1995年 | 602篇 |
1994年 | 533篇 |
1993年 | 458篇 |
1992年 | 509篇 |
1991年 | 414篇 |
1990年 | 331篇 |
1989年 | 274篇 |
1988年 | 279篇 |
1987年 | 265篇 |
1986年 | 205篇 |
1985年 | 218篇 |
1984年 | 179篇 |
1983年 | 134篇 |
1982年 | 117篇 |
1981年 | 95篇 |
1980年 | 70篇 |
1979年 | 62篇 |
1978年 | 72篇 |
1977年 | 53篇 |
1976年 | 52篇 |
1975年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
4.
美国食品药品管理局(FDA)于2022年7月发布了"治疗等效性评价供企业用指导原则"(草案)。该指导原则阐明了FDA治疗等效性的标准以及治疗等效性编码系统,目的是准确评价仿制药与参比制剂的治疗等效性并通过治疗等效性代码,在"橙皮书"中迅速检索到治疗等效的仿制药。而中国目前尚无类似的指导原则,详细介绍FDA该指导原则主要内容,期望对中国加强仿制药的治疗等效性评价和加速完善和实施符合国情的治疗等效性编码系统有所帮助。 相似文献
5.
6.
7.
8.
9.
《Journal of the American Medical Directors Association》2022,23(3):379-386.e3
ObjectivesPreclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.DesignRandomized double-blind placebo-controlled delayed-start study.Setting and ParticipantPatients with mild to moderate probable AD by NINCDS-ADRDA criteria, stable on acetylcholinesterase inhibitors or memantine (n = 125), were randomized to receive MLC901 (early starters) or placebo (delayed starters) for 6 months, followed by a further 6 months when all patients received MLC901, in a delayed-start design (clinical trial registration: ClinicalTrials.gov, NCT03038035).MethodsThe primary outcome measure was occurrence of serious adverse events (SAEs) at 6 months. Secondary outcomes included the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and other assessment scales.ResultsThere was no significant difference in the risk of SAEs between early and delayed starters at month (M) 6 (22.6% vs 27.0%, risk difference ?4.4%, 90% CI –16.9% to 8.3%). Similarly, there was no significant difference in the risk of adverse events and the occurrence of stroke or vascular events between early and delayed starters throughout the 12-month study period. Early starters did not differ significantly on ADAS-Cog from delayed starters at M6 [mean difference (MD) ?1.0, 95% CI –3.3 to 1.3] and M12 (MD –2.35, 95% CI –5.45 to 0.74) on intention-to-treat analysis. Other cognitive assessment scales did not show significant differences.Conclusions and ImplicationsThis study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD. 相似文献
10.
BackgroundHydrogel systems are increasingly gaining visibility involving biomedicine, tissue engineering, environmental treatments, and drug delivery systems. These systems have a three-dimensional network composition and high-water absorption capacity, are biocompatible, allowing them to become an option as photosensitizer carriers (PS) for applications in Photodynamic Therapy (PDT) protocols.MethodsA nanohydrogel system (NAHI), encapsulated with chloroaluminium phthalocyanine (ClAlPc) was synthesized for drug delivery.. NAHI was synthesized using gelatin as based polymer by the chemical cross-linking technique. The drug was encapsulated by immersing the hydrogel in a 1.0 mg.mL−1 ClAlPc solution. The external morphology of NAHI was examined by scanning electron microscopy (SEM). The degree of swelling of the synthesized system was evaluated to determine the water absorption potential. The produced nanohydrogel system was characterized by photochemical, photophysical and photobiologial studies.ResultsThe images from the SEM analysis showed the presence of three-dimensional networks in the formulation. The swelling test demonstrated that the nanohydrogel freeze-drying process increases its water holding capacity. All spectroscopic results showed excellent photophysical parameters of the drug studied when served in the NAHI system. The incorporation efficiency was 70%. The results of trypan blue exclusion test have shown significant reduction (p < 0.05) in the cell viability for all groups treated with PDT, in all concentrations tested. In HeLa cells, PDT mediated by 0,5 mg.mL−1 ClAlPc encapsulated in NAHI showed a decrease in survival close to 95%. In the internalization cell study was possible to observe the internalization of phthalocyanine after one hour of incubation, at 37 °C, with the the accumulation of PS in the cytoplasm and inside the nucleus at both concentrations tested.ConclusionsGiven the peculiar performance of the selected system, the resulting nanohydrogel is a versatile platform and display potential applications as controlled delivery systems of photosensitizer for photodynamic therapy application. 相似文献